Update on study 006. EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC

International Journal of Clinical Practice, Supplement

Volumn , Issue 103, 1999, Pages 10-15

  Staszewski, Schlomo ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LAMIVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

CLINICAL TRIAL; CONCENTRATION LOSS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO; VIRUS LOAD; VOMITING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG COMBINATION; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HUMANS; INDINAVIR; LAMIVUDINE; LIPID METABOLISM; OXAZINES; VIRAL LOAD; ZIDOVUDINE;

EID: 0032585903     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Staszewski S, Morales-Ramirez J, Tashima K et al. A Phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (AZT) + lamivudine (3TC), versus IDV + AZT + 3TC at 24 weeks [DMP 266-006] (Poster) 12th World AIDS Conference, Geneva, June 1998.
2. Morales-Ramirez J, Tashima K, Hardy D et al. A Phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (AZT) + lamivudine (3TC), versus IDV + AZT + 3TC at 36 weeks [DMP 266-006]. 38th ICAAC, San Diego, September 1998.
3. Tashima K, Staszewski S, Stryker R et al. A Phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (SUSTIVA™, EFV) + indinavir (IDV) versus EFV + zidovudine (AZT) + lamivudine (3TC), versus EFV + IDV + AZT at 48 weeks (Study DMP 266-006). (Poster) 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1999.
4. Carr A, Samaras K, Chrisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 351: 1881-1883.